Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor versus aspirin as single antiplatelet therapy after TAVI
2023-509290-22-00Phase 4Authorised
- Sponsor
- Fundación Biomédica Galicia Sur
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial in aortic stenosis (AS) comparing Brilique monotherapy with Adiro monotherapy (2 arms). Primary endpoints: All-cause mortality, Transient ischemic attack or stroke and 3 more. Planned start Jan 2024; status: authorised.
02
Drugs
ticagreloraspirin
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on 2023-509290-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509290-22-00.